The Serum S100B Level as a Biomarker of Enteroglial Activation in Patients with Ulcerative Colitis
   
Yazarlar (12)
Asuman Çelikbilek Bozok Üniversitesi, Türkiye
Mehmet Çelikbilek Bozok Üniversitesi, Türkiye
Seda Sabah Özcan Bozok Üniversitesi, Türkiye
Nermin Tanık Bozok Üniversitesi, Türkiye
Süleyman Baldane Selçuk Üniversitesi, Türkiye
Kemal Deniz Erciyes Üniversitesi, Türkiye
Neziha Yılmaz Bozok Üniversitesi, Türkiye
Ömer Özbakır Erciyes Üniversitesi, Türkiye
Mehmet Yücesoy Erciyes Üniversitesi, Türkiye
Makale Türü Açık Erişim Özgün Makale (SCOPUS dergilerinde yayınlanan tam makale)
Dergi Adı International Journal of Inflammation
Dergi ISSN 2090-8040 Wos Dergi Scopus Dergi
Dergi Tarandığı Indeksler Scopus
Makale Dili İngilizce Basım Tarihi 01-2014
Cilt / Sayı / Sayfa 2014 / 0 / 1–6 DOI 10.1155/2014/986525
Makale Linki https://downloads.hindawi.com/journals/iji/2014/986525.pdf
Özet
Objective. Recent studies have demonstrated that enteric glial cells (EGC) participate in the homeostasis of the gastrointestinal tract. This study investigated whether enteroglial markers, including S100B protein and glial fibrillary acidic protein (GFAP), can serve as noninvasive indicators of EGC activation and disease activity in UC patients. Methods. This clinical prospective study included 35 patients with UC and 40 age- and sex-matched controls. The diagnosis of UC was based on standard clinical, radiological, endoscopic, and histological criteria. Clinical disease activity was evaluated using the Modified Truelove-Witts Severity Index. Serum samples were analyzed for human GFAP and S100B using commercial enzyme-linked immunosorbent assay kits. Results. GFAP was not detected in the serum of either UC patients or controls (P > 0.05). However, we found a significant (P < 0.001) decrease in the serum S100B levels in the UC patients. No correlation between the serum S100B level and the disease activity or duration was observed (P > 0.05). The serum S100B levels did not differ between UC patients with active disease (24 patients, 68.6%) or in remission (11 patients, 31.4%) (P > 0.05). Conclusions. Ulcerative colitis patients had significantly lower serum S100B levels, while GFAP was of no diagnostic value in UC patients.
Anahtar Kelimeler